3 results
Primary Objective: The primary objective of this prospective clinical trial is to determine the pharmacokinetic variability of SXT (960 mg) in patients receiving TB treatment. With these pharmacokinetic parameters, a population model and limited…
primaryTo assess the safety and tolerability of multiple, once-daily oral doses of RDN-929 over 28 days in healthy older adult subjects and early symptomatic AD subjects.secondaryTo assess the plasma and CSF pharmacokinetics (PK) of RDN-929 in…
To assess 1) the feasibility of in vivo measurement of biomechanical properties of the vaginal wall with the use of cutometry (Cutometer MPA 580 4mm) and indentometry (Indentometer IDM 800) and 2) the biomechanical properties of the vaginal wall.